Foundation Medicine Shows Sequencing-based Cancer Test Can ID Clinically Actionable Mutations

The company, which has targeted the second quarter of 2012 for the commercial launch of its sequencing-based cancer test, demonstrated its performance on 75 cancer tissue samples from non-small cell lung cancer, melanoma, and colon cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.